Clinical trial · Interventional
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma
A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma
NCT01667302CI-TRIAL-00009645unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and tolerability of radiotherapy followed by adjuvant chemotherapy in stage I/II NK/T-cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extranodal NK/T-cell Lymphoma, Nasal Type | Extranodal NK-/T-Cell Lymphoma, Nasal Type | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy followed by chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiotherapy followed by chemotherapy
- description
- Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
- interventionNames
- Drug: Radiotherapy followed by chemotherapy
Primary outcomes (1)
- measure
- 3-year Progression-free survival
- timeFrame
- 3 years
Secondary outcomes (3)
- measure
- Overall response rate
- timeFrame
- 3 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age range 14-70 years old * Histological confirmed, previously untreated stage I/II NK/T cell lymphoma in the upper-aerodigestive tract * ECOG performance status 0-1 * Life expectancy of more than 3 months * Without prior history of pancreatitis * Adequate bone marrow and organ functions Exclusion Criteria: * Low risk population (Definition: stage I without local invasion, B symptoms and high LDH level) * Pregnant or lactating women * With contraindication of steroid including uncontrolled diabetes * Serious uncontrolled diseases and intercurrent infection * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
References
Publications (1)
- DERIVEDLiu Y, Xue K, Xia Z, Jin J, Wang J, Sun H, Lv F, Liu X, Cao J, Hong X, Guo Y, Ma X, Zhang Q. Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients. Cancer Med. 2020 Aug;9(15):5400-5405. doi: 10.1002/cam4.3207. Epub 2020 Jun 9. PMID 32519518